Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Biotechnology company Regeneron agreed to buy the assets of 23andMe, the DNA testing company that filed for bankruptcy in March, for $256 million. That’s just 4% of the San Francisco-based startup’s ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

The once-popular genetic testing company will be acquired by Regeneron after filing for bankruptcy, but the questions about ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

The deal would put the DNA data of millions of customers in the hands of a pharmaceutical company, which hopes to supercharge ...